The evaluation of apomorphine for the treatment of erectile dysfunction

Bibliography

• Feldman HA, Goldstein I, Hatzichristou DG, Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151(1):54–61
   PubMed Web of Science ®Google Scholar
• Morales A. Apomorphine to uprima: the development of a practical erectogenic drug: a personal perspective. Int J Impot Res 2001;13(Suppl 3):S29–34
   PubMedGoogle Scholar
• Benassi-Benelli A, Ferrari F. Activation with (+/-)N-n-propyl-nor-apomorphine (NPA) of the male rat copulatory behavior. Experientia 1979;35(5):645–6
   PubMedGoogle Scholar
• Rampin O, Jerome N, Suaudeau C. Proerectile effects of apomorphine in mice. Life Sci 2003;72(21):2329–36
   PubMedGoogle Scholar
• Hsieh GC, Hollingsworth PR, Martino B, Central mechanisms regulating penile erection in conscious rats: the dopaminergic systems related to the proerectile effect of apomorphine. J Pharmacol Exp Ther 2004;308(1):330–8
   PubMedGoogle Scholar
• D'Aquila PS, Panin F, Cossu M, Dopamine D1 receptor agonists induce penile erections in rats. Eur J Pharmacol 2003;460(1):71–4
   PubMedGoogle Scholar
• Ishizuka O, Gu BJ, Nishizawa O, Effect of apomorphine on intracavernous pressure and blood pressure in conscious, spinalized rats. Int J Impot Res 2002;14(2):128–32
   PubMedGoogle Scholar
• Lal S, Ackman D, Thavundayil JX, Effect of apomorphine, a dopamine receptor agonist, on penile tumescence in normal subjects. Prog Neuropsychopharmacol Biol Psychiatry 1984;8(4-6):695–9
   PubMedGoogle Scholar
• Lal S, Laryea E, Thavundayil JX, Apomorphine-induced penile tumescence in impotent patients–preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry 1987;11(2-3):235–42
   PubMedGoogle Scholar
• Apomorphine (TAP holdings). 6a beta-aporphine-10,11-diol hydrochloride hemihydrate, apomorphine hydrochloride, spontane, Uprima. Drugs R D 1999;2(6):415–16
   PubMedGoogle Scholar
• Argiolas A, Hedlund H. The pharmacology and clinical pharmacokinetics of apomorphine SL. BJU Int 2001;88(Suppl 3):18–21
   PubMedGoogle Scholar
• Richards N, Wayman C, Allers KA. Electrophysiological actions of the dopamine agonist apomorphine in the paraventricular nucleus during penile erection. Neurosci Lett 2009;465(3):242–7
   PubMedGoogle Scholar
• d'Emmanuele di Villa Bianca R, Sorrentino R, Roviezzo F, Peripheral relaxant activity of apomorphine and of a D1 selective receptor agonist on human corpus cavernosum strips. Int J Impot Res 2005;17(2):127–33
   PubMedGoogle Scholar
• Stief CG. Central mechanisms of erectile dysfunction: what a clinician may want to know. Int J Impot Res 2003;15(Suppl 2):S3–6
   Google Scholar
• Waller DG, Renwick AG, Hiller K. Medical Pharmacology and Therapeutics. 3rd edition. Saunders Elsevier; London; 2001
   Google Scholar
• Lu W, Jiang W, Chen J, Modulation of brain delivery and copulation by intranasal apomorphine hydrochloride. Int J Pharm 2008;349(1-2):196–205
   PubMedGoogle Scholar
• Campbell A, Kula NS, Jeppsson B, Baldessarini RJ. Oral bioavailability of apomorphine in the rat with a portacaval venous anastomosis. Eur J Pharmacol 1980;67(1):139–42
   PubMedGoogle Scholar
• Heaton JP. Apomorphine: an update of clinical trial results. Int J Impot Res 2000;12(Suppl 4):S67–73
   Google Scholar
• Schlatter E. Treatment of alcoholics with apomorphine using Dent's methods: a preliminary study. Quebec Psychopharmacological Association Meeting; Montreal; 1966
   Google Scholar
• Dula E, Keating W, Siami PF, Efficacy and safety of fixed-dose and dose-optimization regimens of sublingual apomorphine versus placebo in men with erectile dysfunction. The Apomorphine Study Group. Urology 2000;56(1):130–5
   PubMedGoogle Scholar
• Dula E, Bukofzer S, Perdok R, Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol 2001;39(5):558–3; discussion 64
   PubMedGoogle Scholar
• Von Keitz AT, Stroberg P, Bukofzer S, A European multicentre study to evaluate the tolerability of apomorphine sublingual administered in a forced dose-escalation regimen in patients with erectile dysfunction. BJU Int 2002;89(4):409–15
   PubMedGoogle Scholar
• Gontero P, D'Antonio R, Pretti G, Clinical efficacy of Apomorphine SL in erectile dysfunction of diabetic men. Int J Impot Res 2005;17(1):80–5
   PubMedGoogle Scholar
• Hagemann JH, Berding G, Bergh S, Effects of visual sexual stimuli and apomorphine SL on cerebral activity in men with erectile dysfunction. Eur Urol 2003;43(4):412–20
   PubMedGoogle Scholar
• Lammers PI, Rubio-Aurioles E, Castell R, Combination therapy for erectile dysfunction: a randomized, double blind, unblinded active-controlled, cross-over study of the pharmacodynamics and safety of combined oral formulations of apomorphine hydrochloride, phentolamine mesylate and papaverine hydrochloride in men with moderate to severe erectile dysfunction. Int J Impot Res 2002;14(1):54–9; discussion 60
   PubMedGoogle Scholar
• Eardley I, Wright P, MacDonagh R, An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. BJU Int 2004;93(9):1271–5
   PubMedGoogle Scholar
• Perimenis P, Markou S, Gyftopoulos K, Efficacy of apomorphine and sildenafil in men with nonarteriogenic erectile dysfunction. A comparative crossover study. Andrologia 2004;36(3):106–10
   PubMedGoogle Scholar
• Porst H, Behre HM, Jungwirth A, Burkart M. Comparative trial of treatment satisfaction, efficacy and tolerability of sildenafil versus apomorphine in erectile dysfunction–an open, randomized cross-over study with flexible dosing. Eur J Med Res 2007;12(2):61–7
   PubMedGoogle Scholar
• Pavone C, Curto F, Anello G, Prospective, randomized, crossover comparison of sublingual apomorphine (3 mg) with oral sildenafil (50 mg) for male erectile dysfunction. J Urol 2008;179(5 Suppl):S92–4
   Google Scholar
• Giammusso B, Colpi GM, Cormio L, An open-label, randomized, flexible-dose, crossover study to assess the comparative efficacy and safety of sildenafil citrate and apomorphine hydrochloride in men with erectile dysfunction. Urol Int 2008;81(4):409–15
   PubMedGoogle Scholar
• Maclennan KM, Boshier A, Wilton LV, Shakir SAW. Examination of the safety and use of apomorphine prescribed in general practice in England as a treatment for erectile dysfunction. BJU Int 2006;98(1):125–31
   PubMed Web of Science ®Google Scholar
• Kendirci M, Hellstrom WJG. Intranasal apomorphine. Nastech Pharmaceutical. IDrugs 2004;7(5):483–8
   PubMedGoogle Scholar
• Riley A, Main M, Morgan F. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings. J Sex Med 2010;7(4 Pt 1):1508–17
   PubMedGoogle Scholar
• Tellez C, Bustamante ML, Toro P, Venegas P. Addiction to apomorphine: a clinical case-centred discussion. Addiction 2006;101(11):1662–5
   PubMedGoogle Scholar
• Strebel RT, Reitz A, Tenti G, Apomorphine sublingual as primary or secondary treatment for erectile dysfunction in patients with spinal cord injury. BJU Int 2004;93(1):100–4
   PubMedGoogle Scholar
• Lau DHW, Kommu S, Mumtaz FH, The management of phosphodiesterase-5 (PDE5) inhibitor failure. Curr Vasc Pharmacol 2006;4(2):89–93
   PubMedGoogle Scholar
• Kendirci M, Walls MM, Hellstrom WJG. Central nervous system agents in the treatment of erectile dysfunction. Urol Clin North Am 2005;32(4):487–501; vii
   PubMedGoogle Scholar
• Kumar R, Nehra A. Central nervous system agents and erectile dysfunction. Urol Clin North Am 2011;38(2):165–73
   PubMedGoogle Scholar
• Reffelmann T, Kloner RA. Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. Expert Opin Drug Saf 2005;4(3):531–40
   PubMedGoogle Scholar
• Qin W-B, Wang S-Q, Li M, [Aging reduces contents of endogenous CO, cAMP and cGMP in rat penile tissues]. Zhonghua Nan Ke Xue 2009;15(2):122–5
   PubMedGoogle Scholar
• Liu X-B, Wu T-P, Zhan Y-Y, Wang Z-Y. [Cigarette smoke extract reduces NOS activity and CX43 expression in the corporal cavernosum]. Zhonghua Nan Ke Xue 2011;17(4):351–5
   PubMedGoogle Scholar
• Sommer F, Engelmann U. Future options for combination therapy in the management of erectile dysfunction in older men. Drugs Aging 2004;21(9):555–64
   PubMed Web of Science ®Google Scholar
• Steers WD. Viability and safety of combination drug therapies for erectile dysfunction. J Urol 2003;170(2 Pt 2):S20–3; discussion S3
   Google Scholar
• Miner MM, Seftel AD. Centrally acting mechanisms for the treatment of male sexual dysfunction. Urol Clin North Am 2007;34(4):483–96, v
   PubMedGoogle Scholar
• Kolasa T, Matulenko MA, Hakeem AA, 1-aryl-3-(4-pyridine-2-ylpiperazin-1-yl)propan-1-one oximes as potent dopamine D4 receptor agonists for the treatment of erectile dysfunction. J Med Chem 2006;49(17):5093–109
   PubMedGoogle Scholar
• Farrell DJ, Morrissey I, De Rubeis D, A UK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect 2003;46(2):94–100
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Amar E, Eardley I, Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57(5):804–14
   PubMed Web of Science ®Google Scholar
• Hackett G, Kell P, Ralph D, British Society for Sexual Medicine guidelines on the management of erectile dysfunction. J Sex Med 2008;5(8):1841–65
   PubMed Web of Science ®Google Scholar